Buy Retatrutide Peptide 40mg — Synedica Triple-Agonist Injection Pen Kit
The Synedica Retatrutide 40mg Injection Pen Kit is the most advanced format to buy retatrutide peptide for structured laboratory research. Retatrutide (LY3437943) is a synthetic triple-receptor agonist — the only research peptide that simultaneously targets GLP-1, GIP, and glucagon receptors — making it the most mechanistically comprehensive metabolic research compound currently available to purchase in pen format.
Pre-loaded, precision-dosed, and ready to use the moment it arrives. No reconstitution, no bacteriostatic water, no vial measuring. Just a 40mg pre-loaded cartridge with full dose configurability from 2.5mg to 10mg per administration — the cleanest format to buy retatrutide peptide for multi-week research protocols.
What Is Retatrutide? The Triple-Agonist Research Peptide Explained
Retatrutide (compound identifier: LY3437943) is an investigational synthetic peptide developed by Eli Lilly and currently in Phase 3 clinical trials. It is also referred to informally as “GLP-3” or “triple G” in the research community — though the scientifically accurate term is triple-receptor agonist, reflecting its simultaneous activation of three distinct hormone receptor pathways:
- GLP-1 receptor (glucagon-like peptide-1) — studied for insulin secretion stimulation, gastric emptying modulation, and appetite signalling regulation
- GIP receptor (glucose-dependent insulinotropic polypeptide) — studied for insulin release enhancement, lipid metabolism influence, and adipose tissue signalling
- Glucagon receptor — studied for hepatic glucose output regulation, energy expenditure stimulation, and lipolysis pathway activation
This triple-receptor mechanism is what distinguishes retatrutide from all other GLP-class research peptides. Semaglutide targets one receptor. Tirzepatide targets two. Retatrutide targets three — allowing researchers to study coordinated metabolic signalling across multiple pathways simultaneously in a single compound. Phase 2 data published in the New England Journal of Medicine showed an average body weight reduction of up to 17.5% at 24 weeks, with Phase 3 results demonstrating weight loss of up to an average of 71.2 lbs — the most significant outcomes recorded in the GLP class to date in clinical trial settings.
Retatrutide vs Semaglutide vs Tirzepatide — Mechanism Comparison
| Compound | GLP-1 | GIP | Glucagon | Receptor targets |
|---|---|---|---|---|
| Semaglutide | ✓ | — | — | 1 (single agonist) |
| Tirzepatide | ✓ | ✓ | — | 2 (dual agonist) |
| Retatrutide (LY3437943) | ✓ | ✓ | ✓ | 3 (triple agonist) |
Dose Configuration & Research Protocol Guide
The Synedica Retatrutide pen delivers 4 full doses of 10mg from a single 40mg cartridge, with full configurability at 2.5mg, 5mg, 7.5mg, and 10mg per administration. The standard escalation protocol for new research applications begins at 2.5mg for weeks 1–4, advances to 5mg for weeks 5–8, and may increase to 7.5mg or 10mg from week 9 if required by the research design.
| Dose Setting | Per dose | Doses per pen | Protocol stage |
|---|---|---|---|
| 2.5mg | 2.5mg Retatrutide | 16 doses | Weeks 1–4 (starting dose) |
| 5mg | 5mg Retatrutide | 8 doses | Weeks 5–8 |
| 7.5mg | 7.5mg Retatrutide | 5 doses | Weeks 9–13 |
| 10mg | 10mg Retatrutide | 4 doses | Advanced protocol |
What Is Included in the Retatrutide Pen Kit?
- 1 × Pre-loaded 40mg Retatrutide (LY3437943) injection pen
- 12 × Disposable 32 gauge 4mm needles
- 1 × Full instruction and dosing guide booklet
Why Buy Retatrutide Peptide in Pen Format?
Most suppliers sell retatrutide as a lyophilized powder vial requiring reconstitution with bacteriostatic water, separate syringes, and precise dose calculation before every administration. The Synedica pen eliminates every preparation step — pre-loaded, pre-measured, and ready to use. When you buy retatrutide peptide in pen format, you get consistent dose delivery, zero reconstitution variables, and a format purpose-built for structured multi-week research protocols.
- Pre-loaded 40mg cartridge — ready to use immediately, zero preparation required
- Triple-agonist compound — GLP-1, GIP, and glucagon receptor activity in one peptide
- No reconstitution — no bacteriostatic water, no syringes, no measuring equipment
- All-in-one kit — pen, 12 needles, and dosing guide included
- Lowest competition keyword — retatrutide is the newest GLP-class peptide, meaning fewer suppliers and cleaner search results
- Fast USA shipping — in stock, dispatched within 1 business day
R&D Applications
The Synedica Retatrutide 40mg Injection Pen Kit is produced exclusively for the following controlled research and development applications:
- Triple-receptor agonist (GLP-1/GIP/Glucagon) signalling pathway studies
- Multi-pathway metabolic research — comparative single vs dual vs triple agonist models
- Appetite signalling, gastric emptying, and satiety hormone pathway investigation
- Lipid metabolism, adipose tissue signalling, and lipolysis pathway research
- Hepatic glucose output and energy expenditure mechanism studies
- Peptide stability, shelf-life, and formulation robustness evaluation
- Triple-agonist receptor binding affinity and kinetics research
Frequently Asked Questions
Where can I buy retatrutide peptide in pen kit format?
The Synedica Retatrutide 40mg Injection Pen Kit is available directly at synedica.us. It is one of the only pre-loaded retatrutide peptide pen kits available to buy online for research applications — no reconstitution required. In stock with fast USA shipping.
What is retatrutide (LY3437943)?
Retatrutide (LY3437943) is a synthetic triple-receptor agonist peptide developed by Eli Lilly, currently in Phase 3 clinical trials. It simultaneously activates GLP-1, GIP, and glucagon receptors — making it the most mechanistically advanced compound in the GLP peptide class. It is available for research use only and is not approved for human or animal consumption.
How is retatrutide different from tirzepatide and semaglutide?
Semaglutide is a single GLP-1 agonist. Tirzepatide is a dual GLP-1/GIP agonist. Retatrutide is a triple GLP-1/GIP/Glucagon agonist — the only compound in the class that activates all three receptor pathways simultaneously. This makes retatrutide the most comprehensive tool for multi-pathway metabolic signalling research.
How many doses does the 40mg retatrutide pen contain?
At 2.5mg per dose: 16 doses. At 5mg: 8 doses. At 7.5mg: 5 doses. At 10mg: 4 full doses. The standard escalation protocol starts at 2.5mg weekly for the first 4 weeks, advancing to 5mg for weeks 5–8.
Does the retatrutide pen require reconstitution?
No. The Synedica retatrutide peptide pen is pre-loaded and ready to use. No bacteriostatic water, separate syringes, or vial measuring required — the most convenient format for structured multi-week retatrutide research protocols.
Is retatrutide the same as “GLP-3”?
“GLP-3” is an informal media nickname for retatrutide that is scientifically inaccurate. The correct term is triple-agonist — reflecting its simultaneous activation of GLP-1, GIP, and glucagon receptors. Retatrutide’s compound identifier is LY3437943.
Should new researchers start with semaglutide or retatrutide?
Researchers new to GLP-class peptides typically begin with semaglutide (single agonist) to establish baseline data, then progress to tirzepatide (dual agonist), and finally retatrutide (triple agonist) to study multi-pathway interaction. The Synedica pen kit format makes each progression step consistent and reconstitution-free.
⚠️ All Synedica products are produced exclusively for controlled laboratory research and development applications. Not for human or animal consumption. Not evaluated by the FDA. Not intended to diagnose, treat, cure, or prevent any disease.
